-
Fiche maladie | 2015.10.06
MERS-CoV
A new respiratory virus emerged in Saudi Arabia in 2012. It was named MERS-CoV, or Middle East Respiratory Syndrome Coronavirus, and it affects the respiratory tract, causing fever and a cough and proving fatal in 30% of cases. The virus has since been reported in several countries throughout the Middle East. In all, 1,219 cases have been diagnosed, leading to 449 deaths. Several cases have been...
-
News | 2022.05.12
SARS-CoV 2: A booster with a "Lenti-COVID" vaccine candidate induces protective immunity in the respiratory mucosa in a preclinical model
Scientist at the Institut Pasteur- TheraVectys Joint Laboratory have demonstrated the efficacy of their lentiviral candidate vaccine “Lenti-COVID”, administered as an intranasal booster dose six months after primary vaccination with a messenger RNA vaccine, in a pre-clinical model. This intranasal booster induces protective immunity in the respiratory mucosa. These results pave the way for...
-
Document de presse | 2020.05.26
MV-SARS-CoV-2 vaccine candidate: a new partnership between Institut Pasteur, CEPI, Thémis and MSD
Institut Pasteur announces recent advances in the development of one of its candidate vaccines, MV-SARS-CoV-2, using the measles vector, as part of a renewed partnership with CEPI and the companies Thémis and MSD.With over 100 vaccine projects in development worldwide, the development of a vaccine against SARS CoV-2 infection remains a challenge, with many scientific uncertainties ahead. The...
-
Document de presse | 2021.01.25
COVID-19: progress update on the Institut Pasteur's scientific response and vaccine candidate research programs
Since early 2020, the Institut Pasteur has been engaged in research in several of its areas of scientific expertise, including virology, diagnostics, pathophysiology, epidemiology, modeling, therapeutic research and vaccine research. A number of research programs to find a vaccine for SARS-CoV-2, the virus responsible for the COVID-19 epidemic, are under way. In light of the intermediate results...
-
Document de presse | 2015.03.01
Themis Bioscience’s Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases
Phase 1 trial of the vaccine candidate which was developed under an R&D collaboration between Themis Bioscience GmbH and the Institut Pasteur (Paris) shows good immunogenicity, safety and tolerability. Themis Bioscience (‘Themis’), a biotechnology company developing innovative prophylactic vaccines for emerging tropical infections, and the Institut Pasteur, an international...
-
Document de presse | 2014.11.19
A major step forward in fight against Chikungunya fever: Themis Bioscience’s vaccine candidate successful in phase 1
Results presented at international conferences in Philadelphia and in New Orleans. The induction of neutralizing antibodies by a prophylactic Chikungunya vaccine candidate has now been confirmed by the final results of a phase 1 clinical trial, as well as its tolerability and safety. Detailed information of the trial has been presented at two international conferences. The vaccine candidate was...
-
Document de presse | 2005.06.27
Gates millions for vaccine research The fight against hepatitis C and HIV: foundation supports international consortium
The Bill and Melinda Gates Foundation (Seattle, USA) has decided to fund an international research consortium led by the German Research Centre of Biotechnology (GBF) in Braunschweig and the Institut Pasteur in Paris. The long-term goal of the 9 million dollar project is the development of vaccines against Hepatitis C and HIV. Press release Paris, june 28, 2005 “...
-
Document de presse | 2018.06.19
In-Cell-Art, the Institut Pasteur and BioNet-Asia announce the collaborative development of a dengue vaccine candidate
In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies, BioNet-Asia (BNA), an innovative vaccine developer, and the research team led by Dr. Anavaj Sakuntabhai at the Functional Genetics of Infectious Diseases Unit, Institut Pasteur Paris France, (GFMI-IP), announce today the development of Nanotaxi® formulated DNA vaccine to induce strong immune response against...
-
Document de presse | 2021.01.19
COVID-19: a lentiviral vaccine candidate for intranasal administration provides sterilizing protection in animal models
Scientists from the Institut Pasteur-TheraVectys Joint Laboratory recently published in Cell Host & Microbe1 the results of tests, in two preclinical models, of a COVID-19 vaccine candidate using a lentiviral vector administered by nasal route. Their study demonstrates that the vaccine candidate induces antibody response with strong neutralizing activity against SARS-CoV-2, as well as...
-
Document de presse | 2023.09.19
Development of an onco-therapeutic vaccine candidate against human papillomavirus (HPV)-induced cancers, based on preclinical results showing 100% efficacy
The Biotech TheraVectys, in collaboration with Institut Pasteur-TheraVectys Joint Laboratory, has just demonstrated the preclinical efficacy of its "Lenti-HPV-07" lentiviral vector-based vaccine candidate, administered intramuscularly, against cervical and oropharyngeal cancers induced by human papillomavirus (HPV). These results were published in EMBO Molecular Medicine journal on September 7,...